Pehuén Pereyra Gerber

Pehuén Pereyra Gerber

Auto-generated profile, based on publicly available information

Pehuén Pereyra Gerber

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JYJuan Carlos Yam-Puc
Juan Carlos Yam-Puc
ZHZhaleh Hosseini
Zhaleh Hosseini
EHEmily C. Horner
Emily C. Horner
PGPehuén Pereyra Gerber
Pehuén Pereyra Gerber
NBNonantzin Beristain-Covarrubias
Nonantzin Beristain-Covarrubias
JTJames E. D. Thaventhiran
James E. D. Thaventhiran
Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination.